A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT

Y. Kanda, T. Yamashita, Takehiko Mori, T. Ito, K. Tajika, S. Mori, T. Sakura, M. Hara, K. Mitani, M. Kurokawa, K. Akashi, M. Harada

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was started at 5 mg/kg/day when PCR reached 300 copies per ml or when antigenemia reached three positive cells per two slides. A total of 88 patients were randomized into the antigenemia group (n45) or the PCR group (n43). A significantly higher number of patients reached the threshold in the antigenemia group than in the PCR group (73.3 vs 44.2%, P0.0089). However, only three patients (one in the antigenemia group and two in the PCR group) developed early CMV disease. These patients exclusively had colitis and were successfully treated with GCV or foscarnet. The median number of antigenemia-positive cells at the start of GCV was 47 in the PCR group. These findings suggest that antigenemia assay with the current cutoff was too sensitive and led to unnecessary use of GCV. However, the appropriateness of the threshold may be different by the methodology used, and therefore, it is difficult to generalize.

Original languageEnglish
Pages (from-to)1325-1332
Number of pages8
JournalBone Marrow Transplantation
Volume45
Issue number8
DOIs
Publication statusPublished - 2010 Aug

Fingerprint

Ganciclovir
Real-Time Polymerase Chain Reaction
Randomized Controlled Trials
Polymerase Chain Reaction
Infection
Foscarnet
Colitis
Therapeutics

Keywords

  • antigenemia
  • CMV
  • preemptive therapy
  • real-time PCR

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. / Kanda, Y.; Yamashita, T.; Mori, Takehiko; Ito, T.; Tajika, K.; Mori, S.; Sakura, T.; Hara, M.; Mitani, K.; Kurokawa, M.; Akashi, K.; Harada, M.

In: Bone Marrow Transplantation, Vol. 45, No. 8, 08.2010, p. 1325-1332.

Research output: Contribution to journalArticle

Kanda, Y, Yamashita, T, Mori, T, Ito, T, Tajika, K, Mori, S, Sakura, T, Hara, M, Mitani, K, Kurokawa, M, Akashi, K & Harada, M 2010, 'A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT', Bone Marrow Transplantation, vol. 45, no. 8, pp. 1325-1332. https://doi.org/10.1038/bmt.2009.337
Kanda, Y. ; Yamashita, T. ; Mori, Takehiko ; Ito, T. ; Tajika, K. ; Mori, S. ; Sakura, T. ; Hara, M. ; Mitani, K. ; Kurokawa, M. ; Akashi, K. ; Harada, M. / A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. In: Bone Marrow Transplantation. 2010 ; Vol. 45, No. 8. pp. 1325-1332.
@article{4834edc18cd5410f8c22cb9ac3b4c1d6,
title = "A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT",
abstract = "Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was started at 5 mg/kg/day when PCR reached 300 copies per ml or when antigenemia reached three positive cells per two slides. A total of 88 patients were randomized into the antigenemia group (n45) or the PCR group (n43). A significantly higher number of patients reached the threshold in the antigenemia group than in the PCR group (73.3 vs 44.2{\%}, P0.0089). However, only three patients (one in the antigenemia group and two in the PCR group) developed early CMV disease. These patients exclusively had colitis and were successfully treated with GCV or foscarnet. The median number of antigenemia-positive cells at the start of GCV was 47 in the PCR group. These findings suggest that antigenemia assay with the current cutoff was too sensitive and led to unnecessary use of GCV. However, the appropriateness of the threshold may be different by the methodology used, and therefore, it is difficult to generalize.",
keywords = "antigenemia, CMV, preemptive therapy, real-time PCR",
author = "Y. Kanda and T. Yamashita and Takehiko Mori and T. Ito and K. Tajika and S. Mori and T. Sakura and M. Hara and K. Mitani and M. Kurokawa and K. Akashi and M. Harada",
year = "2010",
month = "8",
doi = "10.1038/bmt.2009.337",
language = "English",
volume = "45",
pages = "1325--1332",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT

AU - Kanda, Y.

AU - Yamashita, T.

AU - Mori, Takehiko

AU - Ito, T.

AU - Tajika, K.

AU - Mori, S.

AU - Sakura, T.

AU - Hara, M.

AU - Mitani, K.

AU - Kurokawa, M.

AU - Akashi, K.

AU - Harada, M.

PY - 2010/8

Y1 - 2010/8

N2 - Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was started at 5 mg/kg/day when PCR reached 300 copies per ml or when antigenemia reached three positive cells per two slides. A total of 88 patients were randomized into the antigenemia group (n45) or the PCR group (n43). A significantly higher number of patients reached the threshold in the antigenemia group than in the PCR group (73.3 vs 44.2%, P0.0089). However, only three patients (one in the antigenemia group and two in the PCR group) developed early CMV disease. These patients exclusively had colitis and were successfully treated with GCV or foscarnet. The median number of antigenemia-positive cells at the start of GCV was 47 in the PCR group. These findings suggest that antigenemia assay with the current cutoff was too sensitive and led to unnecessary use of GCV. However, the appropriateness of the threshold may be different by the methodology used, and therefore, it is difficult to generalize.

AB - Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was started at 5 mg/kg/day when PCR reached 300 copies per ml or when antigenemia reached three positive cells per two slides. A total of 88 patients were randomized into the antigenemia group (n45) or the PCR group (n43). A significantly higher number of patients reached the threshold in the antigenemia group than in the PCR group (73.3 vs 44.2%, P0.0089). However, only three patients (one in the antigenemia group and two in the PCR group) developed early CMV disease. These patients exclusively had colitis and were successfully treated with GCV or foscarnet. The median number of antigenemia-positive cells at the start of GCV was 47 in the PCR group. These findings suggest that antigenemia assay with the current cutoff was too sensitive and led to unnecessary use of GCV. However, the appropriateness of the threshold may be different by the methodology used, and therefore, it is difficult to generalize.

KW - antigenemia

KW - CMV

KW - preemptive therapy

KW - real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=77955570946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955570946&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.337

DO - 10.1038/bmt.2009.337

M3 - Article

VL - 45

SP - 1325

EP - 1332

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -